» Articles » PMID: 23182477

C-Jun N-terminal Kinase (JNK)-phospho-c-JUN (ser63/73) Pathway is Essential for FOXP3 Nuclear Translocation in Psoriasis

Overview
Journal J Dermatol Sci
Publisher Elsevier
Specialty Dermatology
Date 2012 Nov 28
PMID 23182477
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Background: In some psoriatic patients, impaired function of FOXP3+ regulatory T cells has been identified without well-uncovered mechanism(s). Meanwhile, dysregulation of FOXP3 nuclear translocation has been observed in some autoimmune syndromes and in some cancer cells.

Objective: To investigate whether there is dysregulation of FOXP3 nuclear translocation in some psoriatic patients and to explore the signal pathway responsible for FOXP3 nuclear translocation.

Methods: CD4+CD25+ T cells were purified from peripheral blood mononuclear cells by magnetic-bead-based method. FOXP3 expression pattern in psoriasis was analyzed by immunohistochemical staining. Transient and stable cell lines were established by exogenous construct transfection and retrovirus infection respectively. Cytoplasmic and nuclear FOXP3 was analyzed by immunoprecipitation, western blot and immunofluorescence.

Results: We observed that some psoriatic patients showed cytoplasmic retention of FOXP3 and these patients had higher serum IL-17 and disease severity. We found that c-Jun N-terminal kinase (JNK) was essential to FOXP3 nuclear translocation. Inhibition of JNK pathway caused cytoplasmic retention of FOXP3. This inhibition could also impair the promotion of FOXP3 nuclear translocation by UVB. Next we found that phospho-c-JUN (ser63/73), main downstream of JNK pathway, could interact with FOXP3 and promoted FOXP3 nuclear translocation.

Conclusion: Our study demonstrated that JNK-phospho-c-JUN (ser63/73) pathway was essential for FOXP3 nuclear translocation in psoriasis. Our study suggested selective manipulation of JNK in Tregs seems to be a promising choice for the development of drugs in the treatment of autoimmune inflammatory diseases.

Citing Articles

Biochanin A Ameliorates Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice by Modulating the NF-κB and MAPK Signaling Pathways.

Walvekar K, Tirunavalli S, Eedara A, Chandra Y, Kuncha M, B R Kumar A Inflammation. 2024; .

PMID: 39017810 DOI: 10.1007/s10753-024-02103-5.


Natural Product-Derived Compounds Targeting Keratinocytes and Molecular Pathways in Psoriasis Therapeutics.

Lee Y, Jung Y, Choi H, Lee J, Lim T, Lee J Int J Mol Sci. 2024; 25(11).

PMID: 38892253 PMC: 11172960. DOI: 10.3390/ijms25116068.


Signaling pathways and targeted therapies for psoriasis.

Guo J, Zhang H, Lin W, Lu L, Su J, Chen X Signal Transduct Target Ther. 2023; 8(1):437.

PMID: 38008779 PMC: 10679229. DOI: 10.1038/s41392-023-01655-6.


Insulin-binding protein-5 down-regulates the balance of Th17/Treg.

Zhu M, Han H, Hu L, Cao Y, Fan Z Front Immunol. 2022; 13:1019248.

PMID: 36389828 PMC: 9664073. DOI: 10.3389/fimmu.2022.1019248.


Catalpol ameliorates psoriasis-like phenotypes via SIRT1 mediated suppression of NF-κB and MAPKs signaling pathways.

Liu A, Zhang B, Zhao W, Tu Y, Wang Q, Li J Bioengineered. 2020; 12(1):183-195.

PMID: 33323018 PMC: 8806253. DOI: 10.1080/21655979.2020.1863015.